StocksWuxi Biologics Cayman Inc02269.HK

02269.HK

Wuxi Biologics Cayman Inc

103.21 -0.50 (-0.48%)
Prices By Xignite, in HKD Market Closed
Trade
S
103.21
B
103.49

Overview

Prev Close103.21
Day's Range102.51 - 105.80
52 Week Range74.73 - 147.77
Average Volume (3m)16.67M
1-Year Return34.25%
Beta0.0793
Market Cap440.03B
P/E Ratio129.3
Revenue9.49B
EPS0.8043
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.715/06/202126/08/202109/11/2021100.00110.00120.00130.00140.00150.00
Chart times in UTC
Industry Biotechnology
CEO Zhi Sheng Chen, PhD
Employees 6,646

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2020: Wuxi Biologics Cayman Inc's revenues increased by 39.61% and amounted to 6.31B. Net income increased by 66.03% to 1.90B. Net assets decreased by NaN to 25.03B and EPS decreased from N/A to 0.45.
02269.HK's Investor Relations
Income StatementBalance SheetCash Flow Statement
Gross Margin
50.11%
Net Profit Margin
22.06%
Operating Margin
34.60%
Return On Investment
8.19%
2017
2018
2019
2020
Total Revenue
1.87B
3B
4.52B
6.31B
Gross Profit
763.18M
1.21B
1.88B
2.85B
Operating Income
475.06M
618.73M
N/A
1.69B
Net Income
291.3M
746.76M
1.15B
1.9B